Glenmark Pharma has received USFDA approval to manufacture and market therapeutical equivalent of Endo Pharmaceutical’s Frova tablets, used to treat migraine headaches. The drug Frovatriptan Succinate Tablets, 2.5 mg, is “therapeutical equivalent of Endo Pharmaceutical’s Frova tablets 2.5 mg which has an estimated market size of $87.8 million for the 12 months ended January 2016.
Company Profile : Glenmark Pharma Ltd
Leave a Reply